Ontario Public Health Association is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Onsite Partners, Inc. is a holding company of behavioral services organizations: Onsite Workshops, Milestones, and Onsite at The Oaks. The Onsite family of brands provides services to thousands of clients annually from the United States and Europe, through in-person and virtual settings. Through these companies, Onsite curates transformational emotional health experiences that combine some of the best therapeutic and clinical minds in the country with its signature healing hospitality. Recently Onsite launched a series of virtual emotional health courses and will be expanding this platform in 2021. Onsite offers experiential group programs, counseling intensives, digital courses, and innovative residential trauma treatment that bolster empathy, self-awareness, compassion, and resilience. Onsite`s mission is to change lives through enhanced emotional health. Onsite`s work has been featured on 20/20, Good Morning America, New York Times, Wall Street Journal, Marie Claire, People, Dr. Phil Show, and The Doctors.
AURA Network Systems is a company that provides a nationwide network utilizing unique, licensed aviation spectrum to accelerate advanced levels of autonomy in the National Airspace System.
Watching your child struggle is hard. FSGC offers professional child counseling in Topeka to help them overcome their unique struggles.
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.